Literature DB >> 3373403

Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the "anemia of prematurity".

S M Rhondeau1, R D Christensen, M P Ross, G Rothstein, M A Simmons.   

Abstract

We used cells from marrow aspirations that had been performed on 10 infants with the "anemia of prematurity" and tested the responsiveness of their erythroid colony-forming units (CFU-E) to recombinant human erythropoietin. For comparison, we also tested marrow-derived CFU-E from five healthy adults, and circulating CFU-E from cord blood of five healthy neonates. CFU-E from the anemic infants had a 50% maximal response at 0.073 +/- 0.024 U erythropoietin per milliliter (mean +/- SD). They were therefore at least as responsive as were CFU-E from adults, which displayed a 50% maximal response at 0.118 +/- 0.076 U/ml, and as were circulating CFU-E of cord blood origin, which had a 50% maximal response at 0.109 +/- 0.047 U/ml. Because CFU-E from infants with the "anemia of prematurity" appeared highly sensitive to erythropoietin in vitro, we propose that its administration to these patients would likely result in a significant increase in erythrocyte production in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373403     DOI: 10.1016/s0022-3476(88)80223-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

1.  Red blood cell transfusions in very and extremely low birthweight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary?

Authors:  A R Franz; F Pohlandt
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-03       Impact factor: 5.747

2.  How I transfuse red blood cells and platelets to infants with the anemia and thrombocytopenia of prematurity.

Authors:  Ronald G Strauss
Journal:  Transfusion       Date:  2008-01-07       Impact factor: 3.157

3.  Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Authors:  Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

4.  In vitro effect of dexamethasone phosphate on hematopoietic progenitor cells in preterm infants.

Authors:  P Papoff; R D Christensen; J Harcum; Y Li
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-01       Impact factor: 5.747

Review 5.  Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity.

Authors:  Robin K Ohls
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 6.  Anaemia of prematurity: pathophysiology and treatment.

Authors:  Ronald G Strauss
Journal:  Blood Rev       Date:  2010-11       Impact factor: 8.250

7.  Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates.

Authors:  Robin K Ohls; Robert D Christensen; John A Widness; Sandra E Juul
Journal:  J Pediatr       Date:  2015-04-25       Impact factor: 4.406

8.  Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants.

Authors:  V P Carnielli; R Da Riol; G Montini
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-07       Impact factor: 5.747

9.  Double blind trial of recombinant human erythropoietin in preterm infants.

Authors:  A J Emmerson; H J Coles; C M Stern; T C Pearson
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

10.  Weekly intravenous administration of recombinant human erythropoietin in infants with the anaemia of prematurity.

Authors:  D Beck; E Masserey; M Meyer; A Calame
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.